Cytokine-induced changes in the ability of astrocytes to support migration of oligodendrocyte precursors and axon growth.
Repair of demyelination in the CNS requires that oligodendrocyte precursors (OPs) migrate, divide and then myelinate. Repair of axon damage requires axonal regeneration. Limited remyelination and axon regeneration occurs soon after injury, but usually ceases in a few days. In vivo and in vitro experiments have shown that astrocytic environments are not very permissive for migration of OPs or for axonal re-growth. Yet remyelination and axon sprouting early after injury occurs in association with astrocytes, while later astrocytes can exclude remyelination and prevent axon regeneration. A large and changing cast of cytokines are released following CNS injury, so we investigated whether some of these alone or in combination can affect the ability of astrocytes to support migration of OPs and neuritic outgrowth. Interleukin (IL) 1alpha, tumour necrosis factor alpha, transforming growth factor (TGF) beta, basic fibroblast growth factor (bFGF), platelet-derived growth factor and epidermal growth factor alone exerted little or no effect on migration of OPs on astrocytes, whereas interferon (IFN) gamma was inhibitory. The combination of IL-1alpha + bFGF was found to be pro-migratory, and this effect could be neutralized by TGFbeta. We also examined neuritic outgrowth from dorsal root ganglion explants in three-dimensional astrocyte cultures treated with cytokines and found that IL-1alpha + bFGF greatly increased axon outgrowth and that this effect could be blocked by TGFbeta and IFNgamma. All these effects were absent or much smaller when OP migration or axon growth was tested on laminin, so the main effect of the cytokines was via astrocytes. The cytokine effects did not correlate with expression on astrocytes of laminin, fibronectin, tenascin, chondroitin sulphate proteoglycan, N-cadherin, polysialyated NCAM (PSA-NCAM), tissue plasminogen activator (tPA) or urokinase (uPA).
Fok-Seang
J
J
Physiological Laboratory, University of Cambridge, UK.
DiProspero
N A
NA
Meiners
S
S
Muir
E
E
Fawcett
J W
JW
D000818:Animals; D001253:Astrocytes / Q000187:drug effects* / Q000502:physiology; D001369:Axons / Q000502:physiology*; D002452:Cell Count / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D002465:Cell Movement / Q000187:drug effects; D016207:Cytokines / Q000494:pharmacology*; D004338:Drug Combinations; D016326:Extracellular Matrix Proteins / Q000378:metabolism; D006133:Growth Substances / Q000494:pharmacology; D007797:Laminin / Q000494:pharmacology; D016685:Mitomycin / Q000494:pharmacology; D016501:Neurites / Q000187:drug effects / Q000502:physiology; D019384:Nucleic Acid Synthesis Inhibitors / Q000494:pharmacology; D009836:Oligodendroglia / Q000502:physiology*; D010960:Plasminogen Activators / Q000378:metabolism; D051381:Rats; D013234:Stem Cells / Q000502:physiology*
D016207:Cytokines; D004338:Drug Combinations; D016326:Extracellular Matrix Proteins; D006133:Growth Substances; D007797:Laminin; D019384:Nucleic Acid Synthesis Inhibitors; D016685:Mitomycin; D010960:Plasminogen Activators